Charles River Laboratories International (CRL) Accumulated Expenses (2009 - 2026)

Charles River Laboratories International has reported Accumulated Expenses for 18 years, with the latest figure at $380.1 million in Q2 2026.

• On a quarterly basis, Accumulated Expenses rose 64.14% year-over-year to $380.1 million in Q2 2026; TTM through Jun 2026 was $380.1 million, a 64.14% increase from a year earlier, with the FY2025 full-year figure at $270.1 million, up 16.41% from the prior year.
• Accumulated Expenses was $380.1 million for Q2 2026 at Charles River Laboratories International, up from $372.4 million in the prior quarter.
• The five-year high for Accumulated Expenses was $380.1 million in Q2 2026, with the low at $190.9 million in Q1 2024.
• Average Accumulated Expenses over 5 years is $240.9 million, with a median of $225.7 million recorded in 2022.
• The sharpest annual moves came in 2022 and 2026: Accumulated Expenses fell 18.15% in 2022, then surged 64.14% in 2026.
• Over 5 years, Accumulated Expenses stood at $219.8 million in 2022, then grew by 3.67% to $227.8 million in 2023, then climbed by 1.84% to $232.0 million in 2024, then increased by 16.41% to $270.1 million in 2025, then surged by 40.73% to $380.1 million in 2026.
• The last three Accumulated Expenses figures came in at $380.1 million (Q2 2026), $372.4 million (Q1 2026), and $270.1 million (Q4 2025), per Business Quant data.